BR112018016398A2 - métodos para o uso de 5'-adenosina difosfato ribose (adpr) - Google Patents
métodos para o uso de 5'-adenosina difosfato ribose (adpr)Info
- Publication number
- BR112018016398A2 BR112018016398A2 BR112018016398A BR112018016398A BR112018016398A2 BR 112018016398 A2 BR112018016398 A2 BR 112018016398A2 BR 112018016398 A BR112018016398 A BR 112018016398A BR 112018016398 A BR112018016398 A BR 112018016398A BR 112018016398 A2 BR112018016398 A2 BR 112018016398A2
- Authority
- BR
- Brazil
- Prior art keywords
- adpr
- methods
- adenosine diphosphate
- diphosphate ribose
- diseases
- Prior art date
Links
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 title abstract 2
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 title abstract 2
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000030533 eye disease Diseases 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000005855 radiation Effects 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 241000701161 unidentified adenovirus Species 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/34—Copper; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
- C07H19/207—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids the phosphoric or polyphosphoric acids being esterified by a further hydroxylic compound, e.g. flavine adenine dinucleotide or nicotinamide-adenine dinucleotide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Virology (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Communicable Diseases (AREA)
- Otolaryngology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662296665P | 2016-02-18 | 2016-02-18 | |
| US201662428721P | 2016-12-01 | 2016-12-01 | |
| PCT/US2017/018253 WO2017143113A1 (en) | 2016-02-18 | 2017-02-17 | Methods for the use of 5'-adenosine diphosphate ribose (adpr) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112018016398A2 true BR112018016398A2 (pt) | 2018-12-18 |
Family
ID=58191671
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112018016398A BR112018016398A2 (pt) | 2016-02-18 | 2017-02-17 | métodos para o uso de 5'-adenosina difosfato ribose (adpr) |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US11110112B2 (enExample) |
| EP (2) | EP3416654B1 (enExample) |
| JP (4) | JP6946353B2 (enExample) |
| KR (2) | KR102622656B1 (enExample) |
| CN (2) | CN108601793B (enExample) |
| AU (2) | AU2017219878B2 (enExample) |
| BR (1) | BR112018016398A2 (enExample) |
| DK (1) | DK3416654T3 (enExample) |
| ES (1) | ES2900524T3 (enExample) |
| HR (1) | HRP20211942T1 (enExample) |
| HU (1) | HUE057052T2 (enExample) |
| IL (2) | IL291574B2 (enExample) |
| LT (1) | LT3416654T (enExample) |
| PL (1) | PL3416654T3 (enExample) |
| PT (1) | PT3416654T (enExample) |
| WO (1) | WO2017143113A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102622656B1 (ko) | 2016-02-18 | 2024-01-10 | 인버사, 인크. | 5'-아데노신 디포스페이트 리보오스 (adpr)의 사용 방법 |
| US10946034B2 (en) * | 2018-03-27 | 2021-03-16 | Invirsa, Inc. | Methods for the use of 5′-adenosine diphosphate ribose (ADPR) |
| KR102789553B1 (ko) * | 2021-09-07 | 2025-04-03 | 주식회사 펄스인마이어스 | 방사선 및/또는 항암 치료 보조 요법으로 아데노신 디포스페이트 리보오스의 활용 |
| US20250250310A1 (en) * | 2023-03-02 | 2025-08-07 | PearlsInMires Co., Ltd. | Combination therapy with adp-ribose binding peptide and adp-ribose for prevention or treatment of cancer |
| WO2026073064A1 (en) * | 2024-09-30 | 2026-04-02 | Invirsa, Inc. | 5'-adenosine diphosphate ribose (adpr) for use in improving visual acuity |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0618214A1 (en) | 1993-04-01 | 1994-10-05 | Merrell Dow Pharmaceuticals Inc. | Unsaturated phosphonate derivatives of purines and pyrimidines |
| JPH07247210A (ja) | 1994-03-09 | 1995-09-26 | Sunstar Inc | 口腔用組成物 |
| WO1999012951A1 (en) | 1997-09-11 | 1999-03-18 | Oxigene, Inc. | Uses of nicotinamide adenine dinucleotide and its analogs for treatment of malignant and infectious diseases |
| DE60015734D1 (de) | 1999-02-26 | 2004-12-16 | Inspire Pharmaceuticals Durham | Verwendung von dinukleotidtriphosphaten, cytidindiphosphaten und adenindiphosphaten zur herstellung einer pharmazeutischen zubereitung zur förderung der schleimauthydratation |
| WO2000077179A2 (en) | 1999-06-16 | 2000-12-21 | Icos Corporation | Human poly(adp-ribose) polymerase 2 materials and methods |
| US6528042B1 (en) | 1999-10-08 | 2003-03-04 | Galileo Laboratories, Inc. | Compositions of flavonoids for use as cytoprotectants and methods of making and using them |
| US7115585B2 (en) | 2000-08-21 | 2006-10-03 | Inspire Pharmaceuticals, Inc. | Compositions for treating epithelial and retinal tissue diseases |
| WO2003011885A1 (en) | 2001-07-25 | 2003-02-13 | Celltech R & D Limited | Non-natural carbon-linked nucleotides and dinucleotides |
| US20030236217A1 (en) | 2002-05-21 | 2003-12-25 | Shalwitz Robert A. | Treatment of mucositis |
| US20070212395A1 (en) | 2006-03-08 | 2007-09-13 | Allergan, Inc. | Ocular therapy using sirtuin-activating agents |
| US20050276762A1 (en) | 2004-06-15 | 2005-12-15 | Tapas Das | Topical compositions containing 5'-adenosine-diphosphate ribose |
| CA2609549A1 (en) | 2005-05-25 | 2006-11-30 | Sirtris Pharmaceuticals, Inc. | Treatment of eye disorders with sirtuin modulators |
| WO2007054814A1 (en) | 2005-11-14 | 2007-05-18 | Centre National De La Recherche Scientifique - Cnrs | Inhibitors of parp activity and uses thereof |
| WO2008154129A1 (en) | 2007-06-08 | 2008-12-18 | Bausch & Lomb Incorporated | Pharmaceutical compositions and method for treating, reducing, ameliorating, alleviating, or preventing dry eye |
| US20110217262A1 (en) | 2010-03-05 | 2011-09-08 | Kornfield Julia A | Treatment of Ocular Surface Disorders by Increasing Conjunctival Vascular Permeability |
| AU2011251622A1 (en) | 2010-05-10 | 2012-12-20 | Radikal Therapeutics Inc. | Lipoic acid and nitroxide derivatives and uses thereof |
| JP6072009B2 (ja) | 2011-05-12 | 2017-02-01 | フォーサイト・バイオセラピューティクス・インコーポレーテッド | ステロイド又は非ステロイド性抗炎症薬のある安定なポビドンヨード組成物 |
| US20160287622A1 (en) | 2013-11-18 | 2016-10-06 | Massachusetts Institute Of Technology | Compositions and methods for treating immune and viral disorders and modulating protein-rna interaction |
| KR102622656B1 (ko) | 2016-02-18 | 2024-01-10 | 인버사, 인크. | 5'-아데노신 디포스페이트 리보오스 (adpr)의 사용 방법 |
| US10946034B2 (en) | 2018-03-27 | 2021-03-16 | Invirsa, Inc. | Methods for the use of 5′-adenosine diphosphate ribose (ADPR) |
-
2017
- 2017-02-17 KR KR1020187022959A patent/KR102622656B1/ko active Active
- 2017-02-17 PT PT177081049T patent/PT3416654T/pt unknown
- 2017-02-17 BR BR112018016398A patent/BR112018016398A2/pt not_active Application Discontinuation
- 2017-02-17 LT LTEPPCT/US2017/018253T patent/LT3416654T/lt unknown
- 2017-02-17 EP EP17708104.9A patent/EP3416654B1/en active Active
- 2017-02-17 IL IL291574A patent/IL291574B2/en unknown
- 2017-02-17 ES ES17708104T patent/ES2900524T3/es active Active
- 2017-02-17 CN CN201780011126.0A patent/CN108601793B/zh active Active
- 2017-02-17 AU AU2017219878A patent/AU2017219878B2/en active Active
- 2017-02-17 WO PCT/US2017/018253 patent/WO2017143113A1/en not_active Ceased
- 2017-02-17 CN CN202311353882.5A patent/CN117482102A/zh active Pending
- 2017-02-17 HR HRP20211942TT patent/HRP20211942T1/hr unknown
- 2017-02-17 EP EP21198288.9A patent/EP3978003A1/en not_active Withdrawn
- 2017-02-17 JP JP2018563379A patent/JP6946353B2/ja active Active
- 2017-02-17 KR KR1020237034890A patent/KR102883682B1/ko active Active
- 2017-02-17 DK DK17708104.9T patent/DK3416654T3/da active
- 2017-02-17 PL PL17708104T patent/PL3416654T3/pl unknown
- 2017-02-17 HU HUE17708104A patent/HUE057052T2/hu unknown
- 2017-02-17 US US15/999,269 patent/US11110112B2/en active Active
-
2018
- 2018-08-10 IL IL261095A patent/IL261095B/en unknown
-
2021
- 2021-08-03 US US17/392,578 patent/US11857561B2/en active Active
- 2021-09-15 JP JP2021149881A patent/JP7222042B2/ja active Active
-
2023
- 2023-02-02 JP JP2023014497A patent/JP7600282B2/ja active Active
- 2023-03-17 AU AU2023201678A patent/AU2023201678B2/en active Active
- 2023-11-07 US US18/503,967 patent/US12370209B2/en active Active
-
2024
- 2024-12-04 JP JP2024210859A patent/JP2025032189A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202206806B (en) | Benzooxazole derivatives as immunomodulators | |
| JOP20230318A1 (ar) | مشتقات تترا هيدرو – إيميدازوبيريدين كمعدِّلات مناعية pd-l1 | |
| MX2021005087A (es) | Compuestos de formula i para usarse en el tratamiento de infecciones por virus arenaviridae y coronaviridae. | |
| BR112018000542A2 (pt) | composições de irna de transtirretina (ttr) e métodos de uso das mesmas para o tratamento ou prevenção de doenças associadas à ttr | |
| BR112018074185A2 (pt) | 3-oxo-2,6-difenil-2,3-di-hidropiridazina-4-carboxamidas | |
| BR112015023753A2 (pt) | composições, formulações e métodos para o tratamento de doenças oculares | |
| CL2019000935A1 (es) | Composición farmacéutica, métodos para tratamiento y usos de la misma. | |
| BR112018016398A2 (pt) | métodos para o uso de 5'-adenosina difosfato ribose (adpr) | |
| BR112017009497A2 (pt) | polinucleotídeos de aadc para o tratamento da doença de parkinson | |
| BR112016025048A2 (pt) | compostos e composições como agonistas do receptor tipo toll7 | |
| MX2020001757A (es) | Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades. | |
| MX391850B (es) | Compuestos para usarse en el tratamiento o mejoramiento de la enfermedad de huntington | |
| PH12016501966A1 (en) | Compounds and compositions as toll-like receptor 7 agonists | |
| BR112019016497A2 (pt) | 2-heteroaril-3-oxo-2,3-di-hidropiridazina-4-carboxamidas para o tratamento de câncer. | |
| MX377916B (es) | Compuestos 4-amino-imidazoquinolina. | |
| BR112021022951A2 (pt) | Composições e métodos para o tratamento de doenças mediadas por atpase | |
| MX2021003152A (es) | Piridazinonas y sus metodos de uso. | |
| BR112018014794A2 (pt) | pirimidinas substituídas com arila para uso em infecção pelo vírus influenza | |
| MX2020011826A (es) | Composiciones de combinacion que comprenden compuestos de bisfluoroalquil-1,4-benzodiazepinona y metodos de uso de las mismas. | |
| BR112018074483A2 (pt) | proteínas f do rsv pré-fusão estabilizadas | |
| AU2016380190A8 (en) | Deuterated compounds for treating cancer and related diseases and conditions, and compositions and methods thereof | |
| BR112017006264A2 (pt) | derivados de nucleosídeo substituído com 4?-vinila como inibidores de replicação de rna do vírus sincitial respiratório | |
| MX388647B (es) | Compuestos utiles para el tratamiento de una infeccion por mannheimia haemolytica o histophilus somni. | |
| CL2018000430A1 (es) | Compuesto de hidroxitriazina y uso médico relacionado. | |
| BR112019006401A2 (pt) | glicinato de metformina, composições farmacêuticas que compreendem o mesmo e métodos de uso do mesmo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI N? 10196/2001, QUE MODIFICOU A LEI N? 9279/96, A CONCESS?O DA PATENTE EST? CONDICIONADA ? ANU?NCIA PR?VIA DA ANVISA. CONSIDERANDO A APROVA??O DOS TERMOS DO PARECER N? 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL N? 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVID?NCIAS CAB?VEIS. |
|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06I | Publication of requirement cancelled [chapter 6.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2631 DE 08/06/2021 POR TER SIDO INDEVIDA. |
|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B07G | Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette] |
Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021 |
|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |